Drug Profile
LY 2510924
Alternative Names: Anti-CXCR4 peptide - Eli Lilly; T-134Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer AstraZeneca; Eli Lilly and Company; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Peptides; Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Renal cell carcinoma; Small cell lung cancer
- No development reported Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (SC)
- 28 Jun 2019 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in USA (SC)
- 05 Jun 2018 Preliminary safety and efficacy data from a phase I trial in Acute myeloid leukaemia presented at the 54th Annual meeting of American Society of Clinical Oncology (ASCO-2018)